Phase 2
N=54
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Bottom Line
View on ClinicalTrials.gov: NCT03077685 ↗Enrolled (actual)
54
Serious AEs
50.0%
Results posted
Jun 2024
Primary outcome: Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- NanoPac® (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- NanOlogy, LLC
- Primary completion
- Mar 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) |
3; 3; 4; 23; 19; 0 | — |
| SECONDARY Target Tumor Assessment |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Plasma Paclitaxel Concentration (pg/mL) |
62.1; 304; 5497.0; 17347.7; 30; 5017.8 | — |
| SECONDARY Pain (Visual Analog Scale) Score |
0; 0; 5.5; 1.2; 0.8; 5.3 | — |
| SECONDARY Serum CA19-9 Level |
248; 24; 2958; 952; 198; 5476 | — |
| SECONDARY Serum CEA Levels |
1.65; 27.1; 4.58; 5.17; 6.69; 4.55 | — |
Summary
Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.
Eligibility Criteria
Inclusion Criteria
- Signed informed consent;
- Age ≥18 years;
- Histologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as documented via imaging (within 6 weeks of Screening);
- Subject not a candidate for surgery;
- Completion of at least one standard of care IV chemotherapy course for subjects in the dose escalation phase of the study. IV chemotherapy will be initiated prior to first NanoPac injection for subjects in the second and third phases. Hematologic recovery must be confirmed prior to study entry;
- Performance Status (ECOG) 0-1 at study entry;
- Life expectancy of at least 3 months;
- Adequate marrow, liver, and renal function at study entry:
- ANC ≥ 1.5 x 109/L
- Hemoglobin ≥ 9.5 grams/dL
- Platelets ≥ 75 x 109/L
- Total bilirubin ≤ 1.5x institutional ULN
- AST/ ALT ≤ 2.5x institutional ULN
- Creatinine ≤ 1.5x institutional ULN
- Effective contraception if the risk of conception exists.
Exclusion Criteria
- Thrombotic or embolic events;
- Acute or subacute intestinal occlusion;
- History of inflammatory bowel disease;
- Known hypersensitivity to study drugs;
- Known drug or alcohol abuse;
- Pregnant or breastfeeding women;
- Previous or concurrent history of non-pancreatic malignancy except for non-melanoma skin cancer.
Data sourced from ClinicalTrials.gov (NCT03077685). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.